COMMUNIQUÉS West-GlobeNewswire

MediWound to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call on March 19 at 8:30 a.m. Eastern Time

13/03/2018 - 21:05

YAVNE, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, [...]

Immunovaccine to Host Investor Event on April 10, 2018 in New York City

13/03/2018 - 21:05

HALIFAX, Nova Scotia, March 13, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced today that it will host an R&D Update and Investor Event for [...]

Athersys Reports Financial Results for Fourth Quarter, Full Year 2017

13/03/2018 - 21:05

Company also announces equity investment and binding letter of intent to expand HEALIOS K.K. collaboration, covered in a separate release Management to host conference call at 4:30 PM EDT today CLEVELAND, March 13, 2018 [...]

AveXis Enters into Licensing Agreement with Genethon

13/03/2018 - 21:01

CHICAGO and ÉVRY, France , March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ: AVXS ) and Genethon today announced they have entered into an exclusive, worldwide license agreement for in vivo gene therapy delivery [...]

GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) Patents

13/03/2018 - 21:01

LONDON and CARLSBAD, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and [...]

Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

13/03/2018 - 21:01

Recruitment completed in European BP-004 registration trial of BPX-501 and rimiducid Positive BPX-501 interim results reported in AML and primary immunodeficiencies GoCAR-T candidate BPX-601 targeting PSCA in pancreatic [...]

Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results

13/03/2018 - 21:01

- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12 - On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. ( [...]

Supernus Announces Proposed Private Offering of $350 Million of Convertible Senior Notes

13/03/2018 - 21:01

ROCKVILLE, Md., March 13, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) (the “Company”), a specialty pharmaceutical company focused on developing and commercializing products for the treatment [...]

Sientra Reports Fourth Quarter and Full Year 2017 Financial Results

13/03/2018 - 21:01

Remains on Track for Full and Final FDA Approval for U.S. Manufactured Implants Received ISO 13485 Certification for Breast Implants and Tissue Expanders Advanced miraDry Integration and Optimization Strategy SANTA [...]

How to Control Oily Skin - 10 Do’s and Don’ts from Dermatologists; American Academy of Dermatology

13/03/2018 - 19:00

ROSEMONT, Ill., March 13, 2018 (GLOBE NEWSWIRE) -- Although oily skin can clog pores and lead to increased acne breakouts, dermatologists from the American Academy of Dermatology say oily skin also has many benefits. [...]

Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing

13/03/2018 - 19:00

SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it has completed a Series [...]

Novozymes A/S’ annual shareholders’ meeting 2018

13/03/2018 - 18:21

Please read the full announcement in the attached PDF 2018_08_Novozymes_annual_shareholders_meeting_EN

CROSSJECT :Information relative au nombre de droits de vote et d'actions composant le capital social

13/03/2018 - 18:18

Communiqué de Presse Information relative au nombre total de droits de vote et d'actions composant le capital social Dijon, le 13 mars 2018 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]

2017: a year of very significant reinforcement of the cash position (€274M at 12.31.2017), with all programs in the Company's pipeline moving forward

13/03/2018 - 17:54

2017: a year of very significant reinforcement of the cash position (€274M at 12.31.2017), with all programs in the Company's pipeline moving forward Financial results reflect in particular the signficiant ramp-up of [...]

2017 : une année marquée par un renforcement très significatif de la trésorerie (274M€ au 31.12.2017), dans un contexte de progression importante de toutes les composantes du pipeline de la Société

13/03/2018 - 17:54

2017 : une année marquée par un renforcement très significatif de la trésorerie (274M€ au 31.12.2017), dans un contexte de progression importante de toutes les composantes du pipeline de la Société Résultats financiers [...]

VALNEVA Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya

13/03/2018 - 17:46

Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya Lyon (France), March 13, 2018 - Valneva SE, a fully integrated commercial stage biotech company focused on [...]

VALNEVA initie une étude clinique de Phase I pour évaluer son candidat vaccin à injection unique contre le Chikungunya

13/03/2018 - 17:46

Valneva initie une étude clinique de Phase I pour évaluer son candidat vaccin à injection unique contre le Chikungunya Lyon, France, 13 mars 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée [...]

Medtronic EVP & President Hooman Hakami to Speak at Oppenheimer Healthcare Conference

13/03/2018 - 17:01

DUBLIN - March 13, 2018 - Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it will participate in the Oppenheimer 28 th Annual Healthcare Conference on Tuesday, March 20, 2018, in New [...]

Medical Prognosis Institute publishes selected financial information for the period 1 July 2017 - 31 December 2017 due to the proposed merger between Medical Prognosis Institute and Oncology Venture

13/03/2018 - 16:40

Hørsholm, Denmark - Medical Prognosis Institute A/S ("MPI") (Nasdaq First North Stockholm: MPI) today publishes selected financial information for the period 1 July 2017 - 31 December 2017 due to the proposed merger [...]